ERBB2 and breast carcinoma: To examine if the inhibitory effects of trastuzumab on the proliferation of HER2+ breast cancer cells are due to the inhibition of the non-canonical HER2 RIP pathway, we constructed GFP-tagged p75 HER2 (671–1255 aa), and ΔNLS p75HER2 (689–1255 aa, p75HER2 with the deletion of NLS) (Figure 6).